Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up

Show simple item record

dc.contributor.author Wu, Lihteh
dc.contributor.author Arevalo, Jose Fernando
dc.contributor.author Roca, Jose Antonio
dc.contributor.author Maia, Mauricio [UNIFESP]
dc.contributor.author Berrocal, Maria Hortensia
dc.contributor.author Rodriguez, Francisco J.
dc.contributor.author Evans, Teodoro
dc.contributor.author Costa, Rogerio Alves [UNIFESP]
dc.contributor.author Cardillo, José Augusto [UNIFESP]
dc.contributor.author PACORES
dc.date.accessioned 2018-06-18T11:35:36Z
dc.date.available 2018-06-18T11:35:36Z
dc.date.issued 2008-02-01
dc.identifier http://dx.doi.org/10.1097/IAE.0b013e3181619bee
dc.identifier.citation Retina-the Journal Of Retinal And Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 28, n. 2, p. 212-219, 2008.
dc.identifier.issn 0275-004X
dc.identifier.uri http://repositorio.unifesp.br/11600/45215
dc.description.abstract Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO).Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months.Results: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P < 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT +/- SD decreased from 461 +/- 211 mu m at baseline to 321 +/- 152 mu m at 1 month, 273 +/- 99 mu m at 3 months, and 277 +/- 114 mu m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT +/- SD decreased from 385 +/- 168 mu m at baseline to 279 +/- 111 mu m at 1 month, 249 +/- 97 mu m at 3 months, and 240 +/- 93 mu m at 6 months (P = 0.011).Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition. en
dc.format.extent 212-219
dc.language.iso eng
dc.publisher Lippincott Williams & Wilkins
dc.relation.ispartof Retina-the Journal Of Retinal And Vitreous Diseases
dc.rights Acesso restrito
dc.subject bevacizumab en
dc.subject branch retinal vein occlusion en
dc.subject macular edema en
dc.subject vascular endothelial growth factor en
dc.title Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up en
dc.type Artigo
dc.contributor.institution Inst Cirugia Ocular
dc.contributor.institution Clin Oftalmol Ctr
dc.contributor.institution Clin Ricardo Palma
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Univ Puerto Rico
dc.contributor.institution Univ Rosario
dc.contributor.institution Hosp Olhos Araraquara
dc.description.affiliation Inst Cirugia Ocular, San Jose, Costa Rica
dc.description.affiliation Clin Oftalmol Ctr, Retina & Vitreous Serv, Caracas, Venezuela
dc.description.affiliation Clin Ricardo Palma, Lima, Peru
dc.description.affiliation Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil
dc.description.affiliation Univ Puerto Rico, San Juan, PR 00936 USA
dc.description.affiliation Univ Rosario, Fdn Oftalmol Nacl, Bogota, Colombia
dc.description.affiliation Hosp Olhos Araraquara, Retinal Diagnost & Treatment Div, Sao Paulo, Brazil
dc.description.affiliationUnifesp Univ Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil
dc.identifier.doi 10.1097/IAE.0b013e3181619bee
dc.description.source Web of Science
dc.identifier.wos WOS:000253460800003



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account